Business Wire

SIGMOLECS®: the Most Advanced Technology Available for Regenerative Medicine

Share

Contrad Swiss, a pharmaceutical company focused on breakthrough, innovative products that reframe the world of medicine, announces a new partnership with Dr JO Serrentino to bring to the market effective biomedical remedies unlike any other.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005031/en/

Photo by Contrad Swiss

Photo by Contrad Swiss

SIGMOLECS® Technology was conceived and engineered by Dr Serrentino exclusively for Contrad Swiss.

SIGMOLECS® uses the highest bioavailable signaling molecules to summon and target biological pathways for precise programming at the cellular level. The result is like a program code of the cells, deploying them to organize into specific patterns. SIGMOLECS® talks to the cells in their language.

ACTV8SKN® – Actuator - contains the exclusive SIGMOLECS® Technology.
ACTV8SKN® is an odorless fluid gel of peptide-bonded amino acids, specifically engineered for a complete signaling spectrum that awakens cell cycles of the skin. It can be used in clinic to enhance procedures or dispensed to patients as a follow up take-home product. Easy to use, a few drops of ACTV8SKN® to cleansed face. The fluid gel will absorb as soon as it is spread.

Information on the development, novel characteristics of SIGMOLECS® Technology and clinical data supporting the long-lasting efficacy of the most advanced regenerative cosmetic available today, can be requested. www.contrad.ch

About Contrad Swiss

Contrad Swiss is the most innovative pharmaceutical corporation specialized in OTC, medical devices, functional cosmetics and dietary supplements. The innovation can be expressed in the formula, in a new way of administration or a novel application. All the products are respected for their solid scientific support and they carry the consumer recognition of quality and convenience.

About Dr JO Serrentino

M.Sc; DVM; Ph.D FAARM; DABRM. Master’s in Biochemistry; Veterinarian; Doctorate in clinical ecology/environmental medicine. Fellow of the American Academy of Regenerative Medicine; Diplomat of the American Board of Regenerative Medicine.

Extensive expertise in the following areas:

  • Protein sequencing and clones for biological new medicine;
  • Peptide inclusion for medicine;
  • Use of cytokines in medicine and therapy and as pathophysiological markers.
  • Biological markers for diagnostics; targeting and research& development;
  • Carrier formulations for enhanced absorption of active principles; formulating, assessment and/or amendment;
  • Molecular manipulation for enhanced biological properties esp. with protein (cytokine) and gene therapy;
  • Metabolic Syndromes and Energy Metabolism;
  • Stem cell extenders and methodologies for clinical application;
  • Orthopaedic biologicals for clinical application in Regenerative Medicine.

Contact information

Carmen Gerardi
Contrad Swiss SA
+41 79 473 4657
Lugano (CH)
carmen.gerardi@contrad.ch

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance22.7.2019 19:00:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs). The use of Biktarvy in patients with known drug resistance is investigational. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “These data presented at IAS provide new information about the treatment of HIV among women and patients with known drug resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “The studies further demonstrate the potential for Biktarvy to be an

IBC Celebrates Young Talent in the Industry22.7.2019 18:36:00 EESTPress release

The media, entertainment and technology industry is changing. Attitudes are shifting, the next generation is consuming content differently to any before them and diverse and exciting content is being created to meet that demand in innovative formats. Driving this change is a new wave of industry talent, honoured at IBC with the first IBC Young Pioneer Award. Recognising the brightest, newest talent in the industry, this award will go to someone who has made a real impact with their passion, ambition and commitment and is making an outstanding contribution to our industry. “What we were looking for in the shortlist was, most importantly, real talent, a stand-out individual making a real difference in the industry,” said David Levine, VP, Programming - Kids, Europe & Africa/UK & Ireland, The Walt Disney Co. Ltd and Chair of the Judging Panel. “But we were also looking for a lasting legacy, for the Young Pioneer to be a leader today and a media guru of the future.” The call for entries so

Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV22.7.2019 18:00:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function. The Phase 1b data demonstrate the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load in vivo. In addition, Gilead presented preclinical data demonstrating that resistance to GS-6207 in vitro did not lead to resistance to other classes of drugs used in the treatment of HIV. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. GS-6207 is an investigational long-acting antiretroviral agent that can be delivered subcutaneously. GS-6207 recently received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) as a potential therapy for heavily treatment-experienced people living with multi-drug resistant HIV. GS-6207 acts in a novel way compared with current

Pacific Drilling Appoints James W. Harris as Chief Financial Officer22.7.2019 16:42:00 EESTPress release

Pacific Drilling S.A. (NYSE: PACD), one of the world’s leading deepwater drilling contractors, today announced that Pacific Drilling’s Board has appointed James W. Harris to serve as the Company’s Senior Vice President and Chief Financial Officer. Mr. Harris replaces Mr. Johannes (John) P. Boots, who, as previously announced, mutually agreed with the Company to step down from his position to pursue other opportunities. Mr. Harris has more than 30 years of experience in the energy industry in a variety of financial leadership, strategic and business planning roles. He most recently served as Executive Vice President, Drilling & Subsea for Forum Energy Technologies, Inc., having previously served Forum as Chief Financial Officer for 12 years. Bernie Wolford, the Company’s Chief Executive Officer, stated, “We sincerely appreciate the many contributions that John has made during his nearly 10-year tenure with Pacific Drilling and we wish him all the best in his future endeavors.” “We are e

U.N. Environment Programme Urged to Protect Nature and Humankind from Electromagnetic Fields (EMF)22.7.2019 14:00:00 EESTPress release

The Advisors to the International EMF Scientist Appeal, representing 248 scientists from 42 nations, have resubmitted The Appeal to the United Nations Environment Programme (UNEP) Executive Director, Inger Andersen, requesting the UNEP reassess the potential biological impacts of next generation 4G and 5G telecommunication technologies to plants, animals and humans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005154/en/ Ronald L. Melnick, PhD, who led the design of the large $30 million NIH/NTP Animal Study, which showed Radio Frequency Radiation emitted by cell phones and wireless devices causes cancer, confirms that the previously held assumption the radiation cannot cause cancer, or other adverse health effects, is wrong. (Photo: Business Wire) There is particular urgency at this time as new antennas will be densely located throughout residential neighborhoods using much higher frequencies, with greater biologica

Moody’s Analytics Wins Credit Data Provider of the Year at Risk Technology Awards22.7.2019 14:00:00 EESTPress release

Moody’s Analytics, a global provider of financial intelligence, has won Credit Data Provider of the Year in the 2019 Risk Technology Awards. It’s one of six categories won, spanning finance, accounting, regulatory, and credit functions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005025/en/ The combined strength of Moody’s Analytics offerings earned the Credit Data Provider of the Year award. “We’re honored by this recognition,” said Jacob Grotta, Managing Director-Head of Risk & Finance Analytics. “Credit data challenges take many forms, and our capabilities are exemplified in a range of award-winning solutions.” Our Data Alliance is among the world’s largest and most comprehensive data consortia. Its global contributors share origination and performance data in C&I, CRE, project finance, asset finance, and other asset classes – and in return receive benchmarking across a host of metrics as well as detailed reports

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom